Eledon Pharmaceuticals Inc 2025年季度报告

ORTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 19800 MacArthur Blvd.,Suite 250Irvine,California This Quarterly Report on Form 10-Q contains “forward-looking statements” as defined by the Private Securities LitigationReform Act of 1995, which statements involve substantial risks and uncertainties. Any statements other than statements ofhistorical or current fact in this Quarterly Report on Form 10-Q are forward looking statements. In some instances, you can identify forward-looking statements by the use of words such as “believes,” “anticipates,” “plans,” “expects,” “estimates,” “intends,”“predicts,” “projects,” “targets,” “could,” “may,” “will,” and similar expressions, although not all forward-looking statements •our product development plans, expectations for and the timing of commencement, enrollment, completion, data, and Although we believe that we have a reasonable basis for each forward looking statement contained in this Quarterly Reporton Form 10-Q, actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including the factors listed under “Risk Factor Summary” below. These risks and uncertainties, as well as other risks anduncertainties that could cause the Company’s actual results to differ significantly from the forward-looking statements containedherein, are described in greater detail in Part II, Item 1A.Risk Factorsin this Quarterly Report on Form 10-Q. expressly disclaims any intent to update any forward-looking statements, whether as a result of new information, future events orotherwise. You are therefore cautioned not to place undue reliance on the forward-looking statements included in this QuarterlyReport on Form 10-Q. The market data and certain other statistical information used in this Quarterly Report on Form 10-Q are based onindependent industry publications, governmental publications, reports by market research firms or other independent sources. Some similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. The following summarizes the principal factors that make an investment in the Company speculative or risky, all of which •We have incurred significant operating losses since our inception and expect that we will continue to incur losses over thenext several years and may never achieve or maintain profitability. •We will require additional funding to be able to complete the development of our lead drug candidate. If we are unable toraise such capital, or if we are unable to do so on acceptable terms, we will be forced to significantly alter our businessstrategy, substantially curtail our current operations, or liquidate and cease operations altogether.•Issuances of our common stock, including common stock that may be issuable pursuant to outstanding warrants or otherconvertible securities as well as shares and warrants issued or issuable in connection with our recent private placement delays in doing so, our business will be materially harmed.•Unfavorable global economic conditions could have a material adverse effect on our business. •Adverse conditions in the financial markets, including bank failures, could adversely affect our liquidity and financialperformance. •Drug development involves a lengthy and expensive process with an uncertain outcome, including failure to demonstratesafety and efficacy to the satisfaction of the U.S. Food and Drug Administration (“FDA”) or similar regulatory authorities •The results of non-clinical studies and early clinical trials of our product candidates may not be predictive of the results oflater-stage clinical trials, and there is a risk that additional non-clinical and/or clinical safety studies will be required by the prior studies.•Delays or difficulties in the enrollment of patients in clinical trials could delay or prevent our receipt of necessary •If serious adverse events or unacceptable side effects are identified during the development of our product candidates, we may need to abandon or limit our development of some of our product candidates.•Our future success depends on our ability to retain executives and key employees and to attract, retain and motivate qualified personnel in the future.•If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, or the approvals may be for anarrow indication, we may not be able to commercialize our product candidates, and our ability to generate revenue may marketing approval of and commercialize our product candidates and affect the prices we may obtain.•Our internal computer systems, or those of our third-party collaborators, service providers, contractors or consultants, mayfail or suffer security breaches, disruptions, or incidents, which could result in a material disruption of our development 3ope